DEDIFFERENTIATED LIPOSARCOMA
Clinical trials for DEDIFFERENTIATED LIPOSARCOMA explained in plain language.
Never miss a new study
Get alerted when new DEDIFFERENTIATED LIPOSARCOMA trials appear
Sign up with your email to follow new studies for DEDIFFERENTIATED LIPOSARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug BTX-A51 tested in rare sarcomas
Disease control OngoingThis early study tests an oral drug called BTX-A51 in 24 people with advanced liposarcoma (a type of fat tissue cancer) that has spread or come back. The main goal is to see if the drug is safe and tolerable at different doses. It focuses on specific genetic subtypes: MDM2-amplif…
Matched conditions: DEDIFFERENTIATED LIPOSARCOMA
Phase: PHASE1 • Sponsor: Michael Wagner, MD • Aim: Disease control
Last updated Jul 02, 2026 03:00 UTC
-
Could a breast cancer drug help fight liposarcoma?
Disease control OngoingThis study tests a drug called abemaciclib in 33 people with dedifferentiated liposarcoma, a rare soft tissue cancer that has spread or cannot be removed by surgery. The drug aims to slow tumor growth or shrink it by at least a quarter. Abemaciclib is not yet approved for this ca…
Matched conditions: DEDIFFERENTIATED LIPOSARCOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Drug combo shows promise in slowing rare sarcomas
Disease control OngoingThis phase 2 trial tests two oral drugs, ribociclib and everolimus, in people with advanced dedifferentiated liposarcoma or leiomyosarcoma who have had at least one prior treatment. The goal is to see if the combination can stop or slow tumor growth. About 48 participants will ta…
Matched conditions: DEDIFFERENTIATED LIPOSARCOMA
Phase: PHASE2 • Sponsor: Fox Chase Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Immunotherapy combo shows promise against rare sarcomas before surgery
Disease control OngoingThis study tests whether giving immunotherapy drugs (nivolumab with or without ipilimumab) and radiation before surgery can help shrink tumors in people with two rare types of sarcoma. About 32 adults with these cancers that can be surgically removed will receive the treatment an…
Matched conditions: DEDIFFERENTIATED LIPOSARCOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New combo therapy targets hard-to-treat liposarcoma
Disease control OngoingThis study tests whether combining two drugs—etrumadenant and zimberelimab—can shrink or slow advanced dedifferentiated liposarcoma that has returned, spread, or can't be removed by surgery. About 16 adults with this rare cancer will receive the treatment. The goal is to see how …
Matched conditions: DEDIFFERENTIATED LIPOSARCOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Promising sarcoma combo study pulled before starting
Knowledge-focused TerminatedThis study was designed for adults with certain types of soft tissue sarcoma that have specific immune cell clusters (TLS) in their tumors. Participants would have received pembrolizumab (immunotherapy) with or without olaparib (a DNA repair blocker) before surgery, followed by m…
Matched conditions: DEDIFFERENTIATED LIPOSARCOMA
Phase: PHASE2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC